Equity Research Biotechnology

Should You Buy MannKind Corporation Stock in 2026?

By CirclFi Research Team · · Updated · 7/13 models active

According to the CirclFi Deep Alpha Valuation Engine, MannKind Corporation (MNKD) scores a robust 8.3/10 on our 32-signal Quality of Company framework. At the current market price of $3.56 and a $1.1B market cap, our analysis maps this fundamental strength against 13 institutional-grade models to determine if a sufficient margin of safety exists.

The short answer: 0 of 7 CirclFi valuation models project upside for MannKind Corporation (MNKD) at $3.56 — the model consensus leans bearish, with a Quality Score of 8.3/10 and Value-Trap risk of 25/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.

Key Takeaways

  • 7 of 7 models suggest overvaluation — majority bearish
  • Quality Score: 8.3/10 — Excellent — top-tier fundamentals
  • Value Trap Risk: 25/100 — Low — manageable risk
  • Fair Value Range: $0.33 – $1.63 (394% spread)

Bullish Models

0 / 7

Bearish Models

7 / 7

Quality Score

8.3 /10

Excellent — top-tier fundamentals

Value Trap Risk

25 /100
Low

Low — manageable risk

Model Consensus

7 /13
Active Models

Avg. confidence: 39%

What Is the Investment Case for MannKind Corporation (MNKD) in 2026?

What Is the Bull Case vs the Bear Case for MannKind Corporation (MNKD)?

Bull case versus bear case for MannKind Corporation (MNKD) at $3.56, derived from 7 active CirclFi valuation models on 2026-09-15.
Bull case Bear case — $0.33 target (-90.7%)
No active model projects meaningful upside for MNKD at $3.56. Bulls would have to argue that qualitative factors the models cannot measure will unlock value. According to the CirclFi Deep Alpha Valuation Engine, the FTNN Topology model sees the stock as overvalued with a fair value of $0.33 (-90.7%), suggesting that the market price embeds overly optimistic growth assumptions.
Industry headwind: binary clinical trial outcomes represents a meaningful risk for MannKind Corporation and its Biotechnology peers.

How Does MNKD Compare to Its Biotechnology Peers?

ACAD ACADIA Pharmaceutica
8.3
TBPH Theravance Biopharma
8.2
TECH Bio-Techne Corporati
8.3
KROS Keros Therapeutics,
8.2
RIGL Rigel Pharmaceutical
8.4
TGTX TG Therapeutics, Inc
8.1
BBOT BridgeBio Oncology T
5.7
AIM AIM ImmunoTech Inc.
4.9

Valuation data pages: ACAD · TBPH · TECH · KROS · RIGL · TGTX · BBOT · AIM · ENVB · EXEL · INCY

See full Biotechnology rankings →

Which Other Stocks Score Like MNKD on Quality?

Closest companies to MNKD’s Quality of Company score of 8.3/10, across all industries.

Why Do CirclFi’s 7 Models Disagree on MNKD?

Spread

394%

Fair Value Range

$0.33 – $1.63

A 394% spread signals high uncertainty. The investment outcome depends heavily on which scenario plays out.

Most Bullish

PWERM

$1.63 (-54.3%)

Most Bearish

FTNN

$0.33 (-90.7%)

What Are the Biggest Risks of Buying MNKD Stock?

Model Disagreement

394% spread signals high variance in projections.

Bearish Consensus

7/7 models suggest overvaluation.

Macro/Sector Risk

Biotechnology headwinds could affect earnings trajectory.

Model Limitations

Backward-looking models cannot predict disruptions.

Want the full 13-model breakdown?

See every fair value, confidence score, and value trap analysis.

View MNKD Data Page →

So Is MannKind Corporation (MNKD) Worth Buying in 2026?

Our valuation engine sends a clear cautionary signal on MannKind Corporation at $3.56. 7/7 models flag overvaluation, median fair value sits at $0.87 (-75.6%), and the risk-reward profile appears unfavorable. Quality at 8.3/10 is the one bright spot, but premium quality at the wrong price can still destroy returns. This is a stock where patience — or avoidance — may be the optimal strategy.

These are quantitative model outputs, not investment recommendations. MannKind Corporation's future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →

What Else Do Investors Ask About MNKD Stock?

Should I buy MNKD stock right now?

Based on CirclFi's multi-model analysis, 0 of 7 models see upside for MNKD at $3.56. No active models currently project upside, suggesting the market price may already reflect or exceed fair value. This is not a buy recommendation — see our full disclaimer.

What are the biggest risks of investing in MannKind Corporation?

Key risks include: limited model coverage (7/13 active), reducing analytical confidence; wide model disagreement (394% spread), signaling high uncertainty; general market and sector-specific risks affecting Biotechnology companies. Always diversify and consult a financial advisor.

How does MNKD compare to its competitors?

Among Biotechnology peers, MNKD holds a Quality Score of 8.3/10. Comparable companies include ACAD (QOC 8.3), TBPH (QOC 8.2), TECH (QOC 8.3). The relative ranking helps investors identify whether MNKD offers better fundamental quality than alternatives in the same sector.

Is MNKD a good long-term investment?

Long-term investment potential depends on fundamental quality and sustainable competitive advantages. MNKD's Quality Score of 8.3/10 is encouraging for long-term holders, indicating consistent profitability, manageable debt, and healthy cash flows. Check our full data page for all 13 model estimates.

What price should I buy MNKD at?

CirclFi does not provide target buy prices or price alerts. However, our 7 active models produce fair value estimates ranging from $0.33 to $1.63. At $3.56, the stock trades above all model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.

Want the complete picture?

See all 13 model estimates, confidence scores, and the full valuation table for MNKD.

View MNKD Data Page Full Terminal — $39/mo

Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →